Conmed Cp: (NASD: CNMD)

$31.99

-0.38 (-1.17%)

Volume 73,305

Jun 17 04:00 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		31.79 - 32.58
	
		52wk Low - High
		24.78 - 34.86
	
		Previous Close
		32.37
	
		Avg. Volume
		140,939
	
		Industry
		MED/DENTAL-SUPP
	
		Market Cap
		897.68 M
	
		Div - Yield
		0.60 - 1.85
	
		Beta
		1.15
	
		P/E (F1)
		17.50
	
		Current Year Est.
		1.85
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		167 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 04/29/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            17.50
                        
                            PEG Ratio
                            1.59
                        
                            Current Year Est.
                            1.85
                        
                            Current Quarter Estimate
                            0.44
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            07-25-2013
                        
                            EPS Last Year
                            1.83
                        
                            Expected Earnings Growth
                            11.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
CONMED Corporation is a medical technology company specializing in instruments and implants for arthroscopic sports medicine, and powered surgical instruments, such as drills and saws, for orthopaedic, ENT and neurosurgery.  The company is also a leading developer, manufacturer and supplier of advanced medical devices, including electrosurgical systems, electrodes for heart monitoring.  The company's products are used in a variety of clinical settings, such as operating rooms, surgery centers, physicians' offices and critical care areas of hospitals.   
Full CNMD Company Report

 Analyst Report on CNMD

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
CNMD Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.44	NA	1.85	2.08
Number of Estimates	1	0	2	1
Low Estimate	0.41	NA	1.85	2.08
High Estimate	0.46	NA	1.85	NA
Year Ago EPS	0.43	0.43	1.80	1.85
EPS Growth	1.16%	NA	2.78%	12.43%

More CNMD Estimates

Average Earnings Estimates for CNMD

EPS Growth for CNMD

Industry Analysis

Name	Symbol	Previous Close
CONMED CORP	CNMD	32.37
LUXOTTICA ADR	LUX	51.10
STAAR SURGICAL	STAA	8.92
COOPER COS	COO	121.53
MWI VET SUPPLY	MWIV	124.67
STERIS CORP	STE	43.90
WEST PHARM SVC	WST	67.26
ALIGN TECH INC	ALGN	35.02
BARD C R INC	BCR	111.04
BECTON DICKINSO	BDX	98.64

Sector:Medical>> Industry:MED/DENTAL-SUPP

COMPARE TICKER vs. Its Peers

Zacks Commentary

HMA to Provide Management Support

Jun 14, 2013

A New High for CR Bard

Jun 14, 2013

Bard Beefs Up Shareholder Return

Jun 13, 2013

Henry Schein and Masimo Ink New Deal

Jun 13, 2013

Cooper Unveils MyDay Lenses

Jun 10, 2013

Cooper Earnings Beat, Rev Misses Est

Jun 07, 2013

Bard Begins Lutonix BTK Trial

Jun 06, 2013

CR Bard Reiterated at Neutral

Jun 05, 2013

More CNMD Zacks Commentary

Financials

EPS TTM	1.83
Sales	767
Net Income	41
Price/Earnings	17.69
Price/Book	1.52
Price/Cash Flow	9.38
Price/Sales	1.18

More CNMD Financials

News

Norway Orthopedic Devices Investment Opportunities, Analysis and Forecasts to 2018 - M2

Jun 11, 2013

This Metric Says You`re Smart to Own CONMED - TheMotleyFool

Jun 11, 2013

CONMED Declares Quarterly Cash Dividend - Close-Up Media

May 30, 2013

CONMED Corporation to Present at the Jefferies 2013 Global HealthcareConference - Marketwire

May 29, 2013

Recent 52-Week High Exceeded in Shares of Conmed (CNMD) - Financial News Netwfork Online - 52-Week High-Lows

May 28, 2013

CONMED Corporation Announces Quarterly Cash Dividend - Marketwire

May 24, 2013

Has CONMED Made You Any Real Money? - TheMotleyFool

May 14, 2013

CONMED reports higher Q1 net income, provides outlook for Q2 and 2013 - Datamonitor

May 10, 2013

See All News Stories on CNMD

Broker Recommendations

Current ABR	2.33
ABR (Last Week)	2.33
# of recs in ABR	3
Average Target Price	34.31
Industry Rank by ABR	167 out of 265
Rank in Industry	3 out of 29

More CNMD Broker Recommendations

Day Low - High	31.79 - 32.58
52wk Low - High	24.78 - 34.86
Previous Close	32.37
Avg. Volume	140,939
Industry	MED/DENTAL-SUPP
Market Cap	897.68 M
Div - Yield	0.60 - 1.85
Beta	1.15
P/E (F1)	17.50
Current Year Est.	1.85
Quarterly Earnings ESP	NA

P/E (F1)	17.50
PEG Ratio	1.59
Current Year Est.	1.85
Current Quarter Estimate	0.44
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	07-25-2013
EPS Last Year	1.83
Expected Earnings Growth	11.00%

Username: Password:

Remember me [?]

Conmed Cp: (NASD: CNMD)

$31.99

-0.38 (-1.17%)

Volume 73,305

Jun 17 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description